Made in Russia antilymphocytic globulin (ALG) was given to 43 patients
with aplastic anemia (AA). 56% of the patients responded, 30% reached
a complete or partial remission. 5-year actural sur vival of ALG-trea
ted patients was 52% (44 and 60% for severe and non-severe forms). The
data on ALG efficacy suggest its benefits in fist-line therapy of bot
h severe and non-severe AA as well as in management of patients resist
ant to other methods of immunosuppressive treatment.